• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 7th June 2019

OHE at the 2019 Health Technology Assessment International (HTAi) Annual Meeting

Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June. Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June.…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June.

Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June.

The 2019 HTAi annual meeting will take place from 15th to 19th June in Cologne, Germany, with the theme HTA Beyond 2020: Ready For The New Decade? Adrian Towse, Lotte Steuten, Margherita Neri, and Mikel Berdud will be attending to present work from some of OHE’s projects.

OS02: Evaluating public health interventions: a neglected area in HTA field

Public health interventions are important for ensuring sustainable healthcare infrastructures, but represent a neglected area in HTA due to various methodological issues and complex design that frequently goes beyond clinically oriented interventions. This presentation will include the results of a cross-sectional survey that aimed to provide a global mapping of HTA initiatives related to the assessment of public health technologies, co-authored by Grace Hampson.

PS32: Adapting HTA and procurement to tackle antimicrobial resistance

There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance, but there is little agreement on how. This poster, co-authored by Adrian, Margherita, Grace, and OHE Visiting Fellow Chris Henshall, reports findings from a literature review, expert interviews, and face-to-face discussions at a forum.

PS32: Value-based policies to support innovations in precision medicine

This policy paper, co-authored by Adrian, proposes principles to support dynamic efficiency in the development, adoption, and use of personalised and precision medicine. These principles define the need for a broader concept of value; flexible, value-based, indication-specific pricing of complementary diagnostic tests and medicines; ongoing real-world evidence generation; and appropriate methods to divide and reward value among complementary diagnostic tests and medicines.

OS19: Aligning value in regulatory and health technology assessments

The recent proliferation of value assessment frameworks with a range of approaches and methods has confused many potential users. This policy analysis, co-authored by Adrian, explores their differences and similarities. Four key decision contexts—regulatory benefit-risk analysis, coverage and reimbursement, treatment guidelines and clinical pathways, and clinical shared decision-making—can be aligned by using the quality-adjusted life year as the central value element.

PS39: Quantifying the life-cycle value of innovative medicines: the case of risperidone and second-generation antipsychotics

This work, led by Mikel, quantifies the value added by risperidone (second-generation antipsychotic) versus haloperidol (first-generation antipsychotic) along its life-cycle. The authors estimate the consumer and producer surplus, the net monetary benefit and the incremental cost-effectiveness ratio, per year and aggregated (1994-2017). Results suggest that market access decisions at launch should consider the value added by innovative medicines over their entire life-cycle.

  • Health Technology Assessment…
  • Value, Affordability, and…
  • Events

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • January 2020

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

Read more
  • News
  • September 2019

OHE Lunchtime Seminar: Closing the ‘Know-do’ Gap for Health Systems Reform at the Policy Level

Read more
  • News
  • August 2019

OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!